|
Number of responders considered at the end of the study (week 4) and at 1 and 2 month(s) after treatment*. |
|||
| 1 month after treatment |
2 months after treatment |
||
|
|
|
||
| Treatment groups |
responders at week 4 |
remaining responders/ evaluated responders† |
remaining responders/ evaluated responders† |
|
|
|||
| Placebo |
13 |
11/12 |
9/12 |
| Diclofenac |
18 |
10/16 |
7/15 |
| EA |
27 |
21/25 |
19/24 |
| Combined |
24 |
14/24 |
14/24 |
|
|
|||
| p value** |
0.12 |
0.19 |
|
|
* Only the responders at the end of the study were followed up for 2 months. †Some patients were unable to be evaluated due to loss of follow up or use of NSAIDs for other purposes during the follow-up period. ** Fisher test between the four groups. | |||
Sangdee et al. BMC Complementary and Alternative Medicine 2002 2:3 doi:10.1186/1472-6882-2-3 |
|||